PBP1A阻害薬のパイプライン・インサイト2017

◆英語タイトル:PBP1A Inhibitors -Pipeline Insights, 2017
◆商品コード:DIMR2016539
◆発行会社(調査会社):DelveInsight
◆発行日:2017年12月
◆ページ数:約60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、世界におけるPBP1A阻害薬のパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・PBP1A阻害薬の概要
・PBP1A阻害薬のパイプライン概要
・企業別開発中のPBP1A阻害薬
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・PBP1A阻害薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・PBP1A阻害薬開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “PBP1A Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the PBP1A Inhibitors. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for PBP1A Inhibitors. DelveInsight’s Report also assesses the PBP1A Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of PBP1A Inhibitors
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the PBP1A Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for PBP1A Inhibitors and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• PBP1A Inhibitors Overview
• PBP1A Inhibitors Disease Associated
• PBP1A Inhibitors Pipeline Therapeutics
• PBP1A Inhibitors Therapeutics under Development by Companies
• PBP1A Inhibitors Filed and Phase III Products
• Comparative Analysis
• PBP1A Inhibitors Phase II Products
• Comparative Analysis
• PBP1A Inhibitors Phase I and IND Filed Products
• Comparative Analysis
• PBP1A Inhibitors Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• PBP1A Inhibitors – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• PBP1A Inhibitors – Discontinued Products
• PBP1A Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for PBP1A Inhibitors
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for PBP1A Inhibitors by Therapy Area, 2017
• Number of Products under Development for PBP1A Inhibitors, 2017
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2017
• Comparative Analysis Phase II Products, 2017
• Comparative Analysis Phase I and IND Filed Products, 2017
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
• Drug Candidates Profiles
• PBP1A Inhibitors Assessment by Monotherapy Products
• PBP1A Inhibitors Assessment by Combination Products
• PBP1A Inhibitors Assessment by Route of Administration
• PBP1A Inhibitors Assessment by Stage and Route of Administration
• PBP1A Inhibitors Assessment by Molecule Type
• PBP1A Inhibitors Assessment by Stage and Molecule Type
• PBP1A Inhibitors Therapeutics – Discontinued Products
• PBP1A Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2017


List of Figures
• Number of Products under Development for PBP1A Inhibitors by Therapy Area, 2017
• Number of Products under Development for PBP1A Inhibitors, 2017
• Filed and Phase III Products, 2017
• Phase II Products, 2017
• Phase I and IND Filed Products, 2017
• Discovery and Pre-Clinical Stage Products, 2017
• PBP1A Inhibitors Assessment by Monotherapy Products
• PBP1A Inhibitors Assessment by Combination Products
• PBP1A Inhibitors Assessment by Route of Administration
• PBP1A Inhibitors Assessment by Stage and Route of Administration
• PBP1A Inhibitors Assessment by Molecule Type
• PBP1A Inhibitors Assessment by Stage and Molecule Type


【レポートのキーワード】

PBP1A阻害薬、医薬品、製薬、研究開発、パイプライン、治療、治験

★調査レポート[PBP1A阻害薬のパイプライン・インサイト2017] (コード:DIMR2016539)販売に関する免責事項を必ずご確認ください。
★調査レポート[PBP1A阻害薬のパイプライン・インサイト2017]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆